ImmunityBio Quarterly Cash Flow Statement
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ImmunityBio free cash flow
In the quarter ended Jun 30, 2026, ImmunityBio generated -$66.5 million of operating cash flow and spent $3.5 million on capital expenditures. That left free cash flow of -$70.0 million, a free-cash-flow margin of -136.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
ImmunityBio cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -230.39M | -632.80M | -61.96M | -67.27M | -92.57M | -129.67M | -59.18M | -85.75M | -134.58M | -134.13M | -233.41M | -95.64M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.41M | 4.38M | 3.87M | 3.95M | 3.88M | 3.83M | 4.14M | 4.46M | 4.41M | 4.55M | 4.56M | 4.58M |
| Stock-Based Compensation | 8.52M | 8.17M | 8.75M | 8.88M | 9.65M | 9.54M | 9.04M | 7.49M | 9.64M | 8.27M | 12.77M | 14.45M |
| Change in Working Capital | -9.43M | -1.78M | -17.47M | -11.35M | -9.51M | -8.40M | -6.38M | -14.99M | 3.33M | 5.95M | -6.38M | -4.51M |
| Operating Cash Flow | -66.49M | -75.36M | -70.38M | -68.91M | -79.75M | -85.91M | -85.14M | -98.76M | -100.35M | -106.98M | -115.27M | -87.40M |
| Capital Expenditures | -3.52M | -1.78M | -903.00K | -741.00K | -1.08M | -1.12M | -2.11M | -2.79M | -724.00K | -1.26M | -7.96M | -5.67M |
| Investing Cash Flow | -107.47M | -31.65M | 43.57M | -181.36M | -16.14M | 4.13M | 9.83M | 65.03M | -51.49M | -35.62M | 2.25M | -15.63M |
| Debt Repaid | -886.00K | -868.00K | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 44.44M | 223.93M | 54.89M | 173.52M | 172.81M | -982.00K | 106.93M | 15.58M | 148.89M | 10.22M | 200.54M | 237.50M |
| Net Change in Cash | -129.52M | 117.04M | 28.09M | -76.81M | 77.00M | -82.77M | 31.61M | -18.14M | -2.93M | -132.42M | 87.49M | 134.47M |
| Free Cash Flow | -70.01M | -77.14M | -71.28M | -69.65M | -80.83M | -87.03M | -87.25M | -101.56M | -101.07M | -108.24M | -123.23M | -93.08M |
This table shows 12 quarterly periods of ImmunityBio's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IBRX's reporting calendar. What is a cash flow statement?